| INTRODUC TI ON
not, 1 and therefore, accuracy and precision are extremely import- 5, 6 although at the time of writing, the best estimate for the release of a new standard is "within 2 years." Until this product becomes available, there is a recognized requirement for a standard product to which patients' Hb A 2 results can be traced.
The purpose of the exercise was to undertake a preliminary as- 
| MATERIAL S AND ME THODS

| WHO reference material 89/666
The WHO International Reference Reagent (WHO IRR) for Hb The WHO IRR is a lyophilized material prepared from human whole blood from an obligate β-thalassaemia carrier that requires reconstitution with 0.5 mL distilled or deionized water before use. It has an assigned Hb A 2 value of 5.3%.
| UK NEQAS survey material
UK NEQAS survey material for Hb A 2 measurement was prepared from a single donation of leucodepleted, citrate phosphate dextrose (CPD) anticoagulated, human whole blood, collected by the National
Health Service Blood and Transplant (NHSBT) from a β-thalassaemia carrier donor who had consented for their blood to be used for EQA purposes. Survey material was not stabilized but was treated with the antibiotics penicillin and gentamycin 7 before being dispensed using a bespoke machine and associated mixing apparatus to maintain homogeneity. Survey material homogeneity and stability was assessed using UK NEQAS Haematology standard protocols on preparation day, dispatch day and survey closing day using a Bio-Rad
Variant II high-performance liquid chromatography (HPLC) analyser running the β-Thalassaemia Short Program (Bio-Rad Laboratories Corporation, CA, USA). 
| Survey distribution
| Statistical analysis
| RE SULTS
| Analysers
Ten analyser types (nine HPLC and one CZE), as listed in Table 1 
| WHO IRR Hb A 2 results
A total of 156 analyses were received from 52 instruments, as shown in Table 2 . Figure 1 shows a box and whisker plot of the results returned by analyser group, where the shaded box shows the median and interquartile range and the length of the whiskers is 1.5 times the interquartile range, rolled back to where there is data, with data values outside the whiskers individually plotted. Figure 3 shows a box and whisker plot by analyser type of the results for 1502AH1, with the all methods trimmed mean Hb A 2 result (5.07%) and the suggested ±0.25% acceptable performance limit shown. In comparison with the acceptable performance limit, a positive bias was seen with both the Tosoh G7 and G8 analysers with 100%
(19/19) and 76% (31/41) results greater than the upper limit of the range, respectively. In contrast, the Menarini HA8160 analyser group showed a negative bias with 61% (17/28) results less than the lower limit; 100% (7/7) of the Menarini HA8180T analysers results
were also less than the lower limit. The Bio-Rad analyser results varied by model: 75% (6/8) of Bio-Rad Classic analyser results were less (all models) were less than the lower limit compared to 2% greater than the upper limit. The Primus Ultra 2 group also showed a negative bias, with 53% (9/17) results less than the lower limit. 
| Evaluation of HPLC chromatograms and CZE electropherograms
The 
| D ISCUSS I ON
The purpose of this exercise was to make a preliminary examination of the only currently available Hb A 2 reference material, the WHO International Reference Reagent (WHO 89/666), which was manufactured in the late 1980s and validated for the manual and limited HPLC methods in use at the time.
The overall mean result returned for the WHO IRR (5.17%) as shown in Table 2 is consistent with the assigned value of 5.3%.
Although a wide range of results was observed, the median result Internal UK NEQAS validation has demonstrated that the CPD-anticoagulated blood is commutable across the major instrument types and comparable to the performance seen with EDTA anticoagulated whole blood. Similar observations of bias between instruments have been described using EDTA anticoagulated samples. CV% results obtained for the whole blood specimen by HPLC methods (3.75%-7.38%) and CZE methods (2.63%) is higher than that reported in previous studies 3, 11 although this probably reflects the greater number and range of instruments included in this study.
The examination of the HPLC chromatograms and the CZE electropherograms showed some evidence of additional peaks in occasional cases; in particular, these were seen for some Bio-Rad Variant II analysers but were not quantitated in all cases. In contrast, peaks were seen and quantitated by other analysers but did not appear to impact on the observed Hb A 2 result. Therefore, it is difficult from the available evidence to say whether there has been significant deterioration of the product and whether this affects all methods to the same degree. can be used to "bridge the gap" until a new standard is produced.
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